Turossi-Amorim Eric Diego, Camargo Bruna, do Nascimento Diego Zapelini, Schuelter-Trevisol Fabiana
State University of Londrina, Tubarao, Brazil.
University of Southern Santa Catarina, Tubarao, Brazil.
J Pharm Technol. 2022 Jun;38(3):159-168. doi: 10.1177/87551225211073942. Epub 2022 Feb 18.
Patients undergoing cancer treatment usually have comorbidities, and psychiatric disorders are commonly seen in these patients. For the treatment of these psychiatric disorders, the use of psychotropic drugs is common, turning these patients susceptible to untoward drug interactions. Therefore, the aim of this study was to estimate the prevalence of clinically relevant drug-drug interactions (DDI) between chemotherapeutic and psychotropic agents in patients with cancer treated at an oncology service in southern Brazil. An observational epidemiological study with a cross-sectional census-type design was carried out between October and December 2020. The drug-drug interactions were identified through consultation and analysis of the Medscape Drug Interaction Check and Micromedex databases. The interactions were classified as major, when the interaction can be fatal and/or require medical intervention to avoid or minimize serious adverse effects and moderate, when the interaction can exacerbate the patient's condition and/or requires changes in therapy. A total of 74 patients was included in the study among the 194 patients seen in the oncology service during the period studied. A total of 24 (32.4%) DDIs were found, 21 (87.5%) of which were classified as being of major risk and 3 (12.5%) as moderate risk. According to the mechanism of action, 19 (79.1%) were classified as pharmacodynamic interactions and 5 (20.9%) as pharmacokinetic interactions. It was shown that a considerable percentage of patients undergoing intravenous chemotherapy are at risk of pharmacological interaction with psychotropic drugs. Thus, it is essential that the oncologist considers all psychotropic drugs and other drugs used by patients in order to avoid drug-drug interactions.
接受癌症治疗的患者通常患有合并症，并且这些患者中常见精神障碍。对于这些精神障碍的治疗，使用精神药物很常见，这使得这些患者容易发生不良药物相互作用。因此，本研究的目的是估计巴西南部一家肿瘤服务机构中接受治疗的癌症患者化疗药物与精神药物之间临床相关药物相互作用（DDI）的发生率。2020年10月至12月进行了一项采用横断面普查型设计的观察性流行病学研究。通过查阅和分析Medscape药物相互作用检查和Micromedex数据库来识别药物相互作用。当相互作用可能致命和/或需要医疗干预以避免或最小化严重不良反应时，将其分类为主要相互作用；当相互作用会加重患者病情和/或需要改变治疗方案时，将其分类为中度相互作用。在研究期间肿瘤服务机构接诊的194例患者中，共有74例患者纳入研究。共发现24例（32.4%）药物相互作用，其中21例（87.5%）被分类为高风险，3例（12.5%）为中度风险。根据作用机制，19例（79.1%）被分类为药效学相互作用，5例（20.9%）为药代动力学相互作用。结果表明，相当比例的接受静脉化疗的患者存在与精神药物发生药理相互作用的风险。因此，肿瘤学家必须考虑患者使用的所有精神药物和其他药物，以避免药物相互作用。
